BGLC
BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of Covid-19, Dengue, human immunodeficiency virus, human papillomavirus, and the risk potentiality of cancers diseases. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming.
BioNexus Gene Lab Corp. (BGLC) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Basic Materials sector peers. Its strongest pillar is Value (B); its weakest is Growth (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.4) | F (0.6) | D+ (1.7) | D- (0.9) | C+ (2.5) | D+ (1.8) |
| 2026-11-10 | B (3.4) | F (0.6) | D+ (1.7) | D (1.2) | C+ (2.5) | C- (1.9) |
| 2026-11-03 | B (3.4) | F (0.5) | D+ (1.7) | D (1.3) | C+ (2.6) | C- (1.9) |
| 2026-10-27 | B- (3.0) | F (0.6) | D+ (1.6) | D+ (1.6) | C+ (2.7) | C- (1.9) |
| 2026-10-20 | B- (3.0) | F (0.6) | D+ (1.6) | D (1.3) | C+ (2.7) | C- (1.9) |